Emerging Trends and Comprehensive Analysis Illuminate Global Irritable Bowel Syndrome Treatment Market Growth Through 2031
January 25, 2024 04:55 ET
|
Research and Markets
Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "Global Irritable Bowel Syndrome Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive...
Global Irritable Bowel Syndrome (IBS) Market Outlook Report 2022-2028: Rising Commercialization of Existing Products in Several Regions is Predicted to Accelerate Growth
March 01, 2022 07:43 ET
|
Research and Markets
Dublin, March 01, 2022 (GLOBE NEWSWIRE) -- The "Global Irritable Bowel Syndrome Market Outlook: Opportunity And Demand Analysis, Market Forecast, 2019-2028" report has been added to...
Sucampo to Host 2017 R&D Day on November 16 in New York
November 09, 2017 17:48 ET
|
Sucampo Pharmaceuticals Inc
ROCKVILLE, Md., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced that it will host its 2017 R&D Day...
Sucampo Reports Third Quarter 2017 Financial Results
November 01, 2017 06:30 ET
|
Sucampo Pharmaceuticals Inc
Company Increases 2017 Financial Guidance Based on Strong Performance Year to Date Study Results for VTS-270 for Niemann-Pick Disease Type C1 Published in The Lancet CPP-1X/sulindac Granted...
Sucampo Pharmaceuticals Announces FDA Acceptance of sNDA for AMITIZA in Children with Pediatric Functional Constipation, with Priority Review Designation
September 28, 2017 17:34 ET
|
Sucampo Pharmaceuticals Inc
ROCKVILLE, Md., Sept. 28, 2017 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced that the U.S. Food and Drug...
Sucampo Reports Second Quarter 2017 Financial Results
August 02, 2017 06:30 ET
|
Sucampo Pharmaceuticals Inc
Patent Issued for Pipeline Compound VTS-270 for Niemann-Pick Disease Type C1 Diluted EPS Loss of $3.92 Resulting from $186.6M IP R&D Second Quarter Charge Due to Accounting Treatment of Vtesse...
Sucampo Reports First Quarter 2017 Financial Results
May 03, 2017 06:30 ET
|
Sucampo Pharmaceuticals Inc
Continued Revenue Growth Recent Vtesse Acquisition Bolsters Pipeline Company Reiterates 2017 Guidance Company to Host Conference Call Today at 8:30 a.m. EDT ROCKVILLE, Md., May 03, 2017 (GLOBE...
Sucampo Reports Fourth Quarter and Full Year 2016 Financial Results
March 08, 2017 06:30 ET
|
Sucampo Pharmaceuticals Inc
Continued Revenue Growth Leads to Strong Income Growth Company Reiterates 2017 Guidance Company Announces Key Executive Transitions Company to Host Conference Call Today at 8:30 a.m. EST ...
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2017 Leerink Global Healthcare Conference
February 09, 2017 06:30 ET
|
Sucampo Pharmaceuticals Inc
ROCKVILLE, Md., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will participate in a fireside...
Sucampo Announces Proposed Convertible Senior Note Offering
December 19, 2016 16:01 ET
|
Sucampo Pharmaceuticals Inc
ROCKVILLE, Md., Dec. 19, 2016 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP), a global biopharmaceutical company, today announced its intention to offer, subject to market and other...